Self proclaimed creator of CrossFit, and the man who thinks he’s leading the 2012 Reebok CrossFit Games, Fitness Lonnie chats to The Rx Review.
More in NEWS
-
The Complete Guide to Finding the Best Deals at Dispensaries
Are you curious about deals at dispensaries? Finding the right options can be exciting yet overwhelming. With so many choices, it’s...
November 25, 2024 -
Exploring Pain Care Management: What Works Best for Body Wellness
Pain is a common issue that affects millions of people worldwide. It can impact your daily activities, mood, and overall well-being....
November 11, 2024 -
10 Benefits of a Holistic Approach to Recovery and Wellness
Taking care of one’s health involves more than just addressing physical symptoms. For lasting well-being, it’s essential to consider how the...
November 6, 2024 -
The Role of Edible Dosage in Therapeutic Treatment Plans
Especially when it comes to drugs that are based on cannabinoids, edible dosage forms have become an important part of therapy...
November 5, 2024 -
How to Claim Compensation for Medical Negligence Affecting Your Fitness
Medical negligence can have profound effects on your overall wellbeing and fitness. If you believe you’ve been a victim of such...
October 24, 2024 -
Fitness After a Spinal Injury: Legal Rights and Compensation Claims
Recovering from a spinal injury can be a daunting journey, both physically and emotionally. In addition to the challenges of rehabilitation,...
October 24, 2024 -
How Medical Negligence Affects Your Health and Fitness Goals
Medical negligence can have profound impacts on your health and fitness aspirations, disrupting both your physical and mental wellbeing. Whether you’re...
October 24, 2024 -
The Psychology Behind Vaping
Vaping, once a niche activity, has grown into a widespread phenomenon, especially among people looking for an alternative to traditional smoking....
October 24, 2024 -
Anavex Life Sciences Reports Once Daily Oral Dementia Treatment Significantly Slows Alzheimer’s Disease Progression
Anavex Life Sciences (Nasdaq: AVXL) recently presented pivotal findings from its Phase IIb/III trial investigating blarcamesine (ANAVEX®2-73), an investigational drug for...
October 22, 2024
Follow Us